When readministering, the original iDose TR implant should always be removed after inserting the new implant. The Food and Drug Administration (FDA) has approved updated labeling for iDose ® TR ...

Shares of Glaukos retreated after the company forecast disappointing sequential revenue growth for its iDose product in the fourth quarter. The stock declined 12% to $97 in after-hours trading on ...

iDose TR, at left, is much smaller than a typical eye drop Shares of Aliso Viejo-based Glaukos Corp. soared 25% on Dec. 14 to a market cap approaching $4 billion (NYSE: GKOS), after the maker of ...

SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here. Designed ...

Glaukos GKOS recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials evaluating its latest approved product, iDose TR. The company also ...

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its targeted injectable implant candidate — iDose TR — in glaucoma patients. Data from the studies showed ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

(RTTNews) - Glaukos Corp. (GKOS), Wednesday announced that the U.S. Food and Drug Administration has approved an NDA labeling supplement allowing for re-administration of iDose TR using a repeat ...

See full labeling. Give as intracameral inj through a small, clear corneal incision. Do not readminister to an eye that has received prior iDose TR. Narrow iridocorneal angles (Shaffer grade <3) or ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...